150 related articles for article (PubMed ID: 15309021)
1. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach.
Zhang H; Liu J; Cagle PT; Allen TC; Laga AC; Zander DS
Mod Pathol; 2005 Jan; 18(1):111-8. PubMed ID: 15309021
[TBL] [Abstract][Full Text] [Related]
2. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material.
Kalhor N; Zander DS; Liu J
Mod Pathol; 2006 Aug; 19(8):1117-23. PubMed ID: 16680154
[TBL] [Abstract][Full Text] [Related]
3. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung.
Wu M; Wang B; Gil J; Sabo E; Miller L; Gan L; Burstein DE
Am J Clin Pathol; 2003 May; 119(5):696-702. PubMed ID: 12760288
[TBL] [Abstract][Full Text] [Related]
4. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors.
Wang BY; Gil J; Kaufman D; Gan L; Kohtz DS; Burstein DE
Hum Pathol; 2002 Sep; 33(9):921-6. PubMed ID: 12378518
[TBL] [Abstract][Full Text] [Related]
5. p63 immunostaining in destained bronchoscopic cytological specimens.
Shtilbans V; Szporn AH; Wu M; Burstein DE
Diagn Cytopathol; 2005 Apr; 32(4):198-203. PubMed ID: 15754365
[TBL] [Abstract][Full Text] [Related]
6. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis.
Kadota K; Nitadori J; Rekhtman N; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2015 Sep; 39(9):1170-80. PubMed ID: 25871623
[TBL] [Abstract][Full Text] [Related]
7. p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma.
Emanuel P; Wang B; Wu M; Burstein DE
Mod Pathol; 2005 May; 18(5):645-50. PubMed ID: 15529180
[TBL] [Abstract][Full Text] [Related]
8. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.
Kaufmann O; Fietze E; Mengs J; Dietel M
Am J Clin Pathol; 2001 Dec; 116(6):823-30. PubMed ID: 11764070
[TBL] [Abstract][Full Text] [Related]
9. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
[TBL] [Abstract][Full Text] [Related]
10. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
[TBL] [Abstract][Full Text] [Related]
11. Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma.
Harlamert HA; Mira J; Bejarano PA; Baughman RP; Miller MA; Whitsett JA; Yassin R
Acta Cytol; 1998; 42(6):1382-8. PubMed ID: 9850647
[TBL] [Abstract][Full Text] [Related]
12. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
Argon A; Nart D; Veral A
Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
[TBL] [Abstract][Full Text] [Related]
13. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers.
Wu M; Szporn AH; Zhang D; Wasserman P; Gan L; Miller L; Burstein DE
Diagn Cytopathol; 2005 Oct; 33(4):223-7. PubMed ID: 16138374
[TBL] [Abstract][Full Text] [Related]
14. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
Mukhopadhyay S; Katzenstein AL
Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
[TBL] [Abstract][Full Text] [Related]
15. Assessment of p63 expression in oral squamous cell carcinomas and dysplasias.
Bortoluzzi MC; Yurgel LS; Dekker NP; Jordan RC; Regezi JA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Dec; 98(6):698-704. PubMed ID: 15583543
[TBL] [Abstract][Full Text] [Related]
16. Progenitor stem cell marker expression by pulmonary carcinomas.
Moreira AL; Gonen M; Rekhtman N; Downey RJ
Mod Pathol; 2010 Jun; 23(6):889-95. PubMed ID: 20305619
[TBL] [Abstract][Full Text] [Related]
17. p63 expression in assessment of bronchioloalveolar proliferations of the lung.
Sheikh HA; Fuhrer K; Cieply K; Yousem S
Mod Pathol; 2004 Sep; 17(9):1134-40. PubMed ID: 15205681
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance and accuracy of p63 and TTF-1 for better approach of small cell lung carcinoma versus poorly differentiated nonkeratinizing squamous cell carcinoma.
Gurguş D; Grigoraş ML; Motoc AGM; Zamfir CL; Cornianu M; Faur CI; Pop DL; Folescu R
Rom J Morphol Embryol; 2019; 60(1):139-143. PubMed ID: 31263838
[TBL] [Abstract][Full Text] [Related]
19. The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears.
Uke M; Rekhi B; Ajit D; Jambhekar NA
Cytopathology; 2010 Feb; 21(1):56-63. PubMed ID: 19744186
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas.
Chen YK; Huse SS; Lin LM
Clin Otolaryngol Allied Sci; 2003 Oct; 28(5):451-5. PubMed ID: 12969350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
